醛氢叶酸5-氟脲嘧啶和顺铂联合同步放疗治疗22例Ⅲ_A期胃癌的疗效观察

Concurrent Chemoradiotherapy for 22Cases of Limited-Advanced Gastric Carcinoma

目的:采用同步放、化疗的模式作为ⅢA期胃癌患者D2根治术后的辅助治疗,并与常规术后辅助化疗相比较观察疗效。方法:46例D2根治术后的ⅢA期胃癌患者随机分为A组(同步治疗组:醛氢叶酸LV+5-FU+DDP联合同步放疗,DT45Gy/25次·35天)和B组(对照组LV+5-FU+DDP化疗)进行治疗。结果:A组和B组的1年生存率(OS)为90.9%和83.3%;3年生存率为80.0%和40.0%,两组比较有显著性差异(P<0.05)。A组和B组的1年无进展生存率(DFS)为81.8%和50.0%;3年无进展生存率为60.0%和20.0%,两组比较均有显著性差异(P<0.05)。结论:同步放、化疗是ⅢA期胃癌患者D2根治术后较为理想的辅助治疗模式。

Objective:To study the results of concurrent chemoradiotherapy for limited-ad-vanced(stageⅢ A )gastric carcinoma.Methods:From March1997to March1999,46cases which are stageⅢ A gastric cancer operated by D 2 gastrectomy randomized into two groups.In group A(22cases)received concurrent chemoradiotherapy(LV+5-FU+DDP and DT45Gy /25f/35d),and in group B(24cases)received adjuvant chemotherapy only(LV+5-FU+DDP).Results:The1-year and3-year survival rate of the two groups are90.9%Vs 83.3%(P>0.05)and80.0%Vs 40.0%(P<0.05);The1-year and3-year disease-free survival rate of the two groups are81.8%Vs 50.0%(P<0.05)and60.0%Vs 20.0%(P<0.05).There is no significant difference in toxicity and side effect.Conclusion:These results demonstrate that concurrent chemoradiotherapy is obviously better than adjuvant chemotherapy alone to those patients who are limited-advanced gastric carcinoma.